Agios Pharmaceuticals Inc. announced the conclusion of its initial public offering (IPO) of 6,772,221 shares of the company's common stock at a final offering price of US$18 per share. This was before underwriting discounts which included the 883,333 shares of common stock issued in full by the underwriters of their option to buy additional shares at the public offering rate, minus the underwriting discount.

Agios Pharmaceuticals Inc., a biopharmaceutical company, focuses on applying its expertise in the cellular metabolism to transforms the lives of patients suffering from inborn errors of metabolism (IEMs). It is one of the leaders in the field of cancer metabolism which is a recent discovery in the field of biology that provides a novel approach to the treatment of cancer.

The company hired J.P Morgan and Goldman Sachs & Co. to fulfill the role of book-running managers for the IPO. Leerink Swan and Cowen and Company acted as co-managers.

The Securities and Exchange Commission declared the registration statement made regarding these securities.